Patent: 10,512,630
✉ Email this page to a colleague
Summary for Patent: 10,512,630
Title: | Compositions and methods for treating cancer |
Abstract: | Provided herein, inter alia, are compositions and methods useful for treating hyperproliferative diseases, including cancer and non-malignant hyperproliferative diseases. |
Inventor(s): | Pietras; Richard J. (Sherman Oaks, CA), Jung; Michael E. (Los Angeles, CA), Marquez-Garban; Diana C. (Los Angeles, CA), Deng; Gang (Los Angeles, CA) |
Assignee: | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) |
Application Number: | 15/764,724 |
Patent Claims: | see list of patent claims |
Details for Patent 10,512,630
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-09-30 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-09-30 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2035-09-30 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2035-09-30 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2035-09-30 |
Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | 06/08/2012 | ⤷ Try a Trial | 2035-09-30 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | ⤷ Try a Trial | 2035-09-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |